Study to Evaluate the Safety and Efficacy of KITE-439 in HLA-A*02:01+ Adults With Relapsed/Refractory HPV16+ Cancers

Inclusion Criteria

• Advanced cancer defined as relapsed or refractory disease after at least 1 line of therapy that included systemic chemotherapy and that is not amenable to definitive locoregional therapy
• HPV16+ tumor as confirmed by the central laboratory
• HLA type is HLA-A*02:01+ per local assessment
• Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 Key

Exclusion Criteria

• Presence of fungal, bacterial, viral, or other infection requiring anti-microbials for management
• Note: Simple urinary tract infection (UTI) and uncomplicated bacterial pharyngitis are permitted if responding to active treatment and after consultation with the Kite medical monitor
• Primary immunodeficiency
• History of autoimmune disease (eg, Crohns, rheumatoid arthritis, systemic lupus) resulting in end organ injury or requiring systemic immunosuppression/systemic disease modifying agents within the last 2 years prior to enrollment
• Known history of infection with human immunodeficiency virus (HIV), hepatitis B (HBsAg positive), or hepatitis C (anti-HCV positive). A history of treated hepatitis B or hepatitis C is permitted if the viral load is undetectable per quantitative polymerase chain reaction (qPCR) and/or nucleic acid testing Note: Other protocol defined Inclusion/Exclusion criteria may apply.